8.24
1.20%
-0.10
시간 외 거래:
8.24
Redhill Biopharma Ltd Adr 주식(RDHL)의 최신 뉴스
COVID-19 Competitive Landscape 2024 (Updated) - openPR
BARDA funds RedHill's opaganib for Ebola treatment - Investing.com
Medi-Cal extends Talicia access for 15 million Californians - Investing.com
RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines - StockTitan
Can Redhill Biopharma Ltd. ADR Bounce Back? 52-Week Performance and Analyst Predictions - The InvestChronicle
RDHL stock’s current quarter earnings estimates: What analysts predict? - US Post News
Talicia® Launched in the United Arab Emirates - StockTitan
Taking on analysts’ expectations and winning: Redhill Biopharma Ltd. ADR (RDHL) - SETE News
Redhill Biopharma stock hits 52-week high of $8.03 amid volatility - Investing.com
Opaganib shows promise in obesity, diabetes treatment - Investing.com India
Balance Sheet Breakdown: Redhill Biopharma Ltd. ADR (RDHL)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Redhill Biopharma Ltd. ADR’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle
Teva Pharmaceutical Industries Limited (TEVA) Stock Price, News, Quote & History - Yahoo Finance
Its Stock Has Paid Off Big Time For Teck Resources Ltd - SETE News
Are Smart Investors Making the Right Decision? Redhill Biopharma Ltd. ADR (RDHL) - SETE News
Check Out Aveanna Healthcare Holdings Inc (AVAH)’s Trade Data Rather Than the Analysts’ Views - SETE News
RDHL’s Stock Tango: The Dance of Gains and Losses in 2023 - The InvestChronicle
Can you now get a good deal on Redhill Biopharma Ltd. ADR’s shares? - US Post News
Is ThredUp Inc (TDUP) positioned for future growth? - SETE News
A look into Redhill Biopharma Ltd. ADR (RDHL)’s deeper side - SETE News
Immuneering Corp (IMRX) expanding its growth trajectory ahead - SETE News
Cipher Mining Inc (CIFR) is looking forward to a strong quarter - SETE News
Nothing is Better Than Hut 8 Corp (HUT) stock at the moment - SETE News
Analytical Overview: Redhill Biopharma Ltd. ADR (RDHL)’s Ratios Tell a Financial Story - The Dwinnex
Redhill Biopharma Ltd. ADR [RDHL] Revenue clocked in at $35.52 million, down -68.49% YTD: What’s Next? - The DBT News
Redhill Biopharma Ltd. ADR Inc. (RDHL) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Should investors be concerned about RDHL’s high price-to-sales ratio? - US Post News
Exact Sciences Corp. (EXAS) Stock: A Year of Decreases and Increases - The InvestChronicle
New Outlook On Alibaba Group Holding Ltd ADR - Stocks Register
Baker Hughes Co (NASDAQ: BKR) Up 1.26%: This Is What Analysts Are Now Forecasting - Stocks Register
Redhill Biopharma Ltd. ADR (RDHL) requires closer examination - US Post News
Redhill Biopharma Ltd. ADR (RDHL) Stock: A Year of Market Fluctuations - The InvestChronicle
Ratio Examination: Redhill Biopharma Ltd. ADR (RDHL)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
RedHill Biopharma finalizes agreement to enhance cash position - Investing.com India
Redhill Biopharma Ltd. ADR (RDHL)'s stock performance: a year in review – US Post News - US Post News
RedHill's (RDHL) RHB-204 Gets FDA Orphan Drug Designation - Yahoo Lifestyle UK
Ratio Analysis: Unpacking Redhill Biopharma Ltd. ADR (RDHL)'s Price-to-Cash and Price-to-Free Cash Flow – DWinneX - The Dwinnex
Should investors be concerned about Redhill Biopharma Ltd. ADR (RDHL)? – US Post News - US Post News
RedHill (RDHL) Down on Unsatisfactory Data From COVID-19 Study - Yahoo News UK
Emerging Technologies in the Proton Pump Inhibitors Market to Hit US$ 3.5 Billion by 2031 - openPR
The Psychology of Redhill Biopharma Ltd. ADR Inc. (RDHL) Price Performance: Understanding Market Sentiment - The InvestChronicle
Proton Pump Inhibitors Market In-depth Analysis, Rising Business Opportunities And Estimated Forecast Till 2031 ... - openPR
Redhill Biopharma Ltd. ADR (RDHL) requires closer examination – US Post News - US Post News
RedHill Biopharma secures $1.25 million in direct offering By Investing.com - Investing.com
KALA Stock Quote Price and Forecast - CNN
RedHill secures new US patent for H. pylori treatment Talicia - Investing.com
RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042 - PR Newswire
symbol__ Stock Quote Price and Forecast - CNN
RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034 - Yahoo Finance
LLY Stock Quote Price and Forecast - CNN
RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S. - PR Newswire
Phil and RedHill Biopharma Partner to Increase Access to Talicia® - Business Wire
Peptic Ulcer Drugs Market Drivers Analysis | CAGR of 3.5% - Market.us
RedHill Biopharma Announces Plan to Implement ADS Ratio Change - PR Newswire
RedHill’s Aemcolo® Granted FDA QIDP 5-Year Exclusivity Extension - BioSpace
RedHill presents New Talicia® and Movantik® data analyses at ACG 2022 - EurekAlert
RedHill presents new Talicia® data analyses at DDW 2022 - EurekAlert
RedHill Biopharma Stock: Looking At An Unexciting Dead-End (NASDAQ:RDHL) - Seeking Alpha
RedHill Biopharma Data Published in GastroHep Shows Consistent Efficacy of Talicia Irrespective of Patient BMI - BioSpace
자본화:
|
볼륨(24시간):